INCY logo

Incyte Corporation

INCY
Healthcare|Biotechnology|US
$119.65
+1.64 (+1.39%)
DCF Value
$113.08
Tangible Book / Share
$26.60
Graham Number
$35.21
Cash / Share
$18.97

Financials

Financial Snapshot

Market Cap
$24.39B
Enterprise Value
$21.15B
Revenue (TTM)
$6.01B
Net Income (TTM)
$403.4M
Cash & Investments
$3.85B
Net Cash
$3.82B
Free Cash Flow (TTM)
$684.9M
Operating CF (TTM)
$745.0M
Debt/Equity
0.01

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$808.5M$1.17B$1.44B$2.12B$1.80B$2.35B$3.24B$3.66B$2.16B$3.58B$3.85B
Operating Cash Flow
$304.8M-$93.0M$336.2M$710.7M-$124.6M$749.5M$969.9M$496.5M$335.3M$1.41B$745.0M
Free Cash Flow
$184.5M-$204.0M$262.7M$632.6M-$312.0M$568.5M$892.1M$464.0M$249.1M$1.35B$684.9M
Capital Expenditure
-$120.3M-$111.0M-$73.5M-$78.1M-$187.4M-$181.0M-$77.8M-$32.5M-$86.3M-$58.9M-$60.1M
Financing Cash Flow
$58.6M$690.2M$14.7M$45.7M$71.7M$6.2M-$794.0K-$20.0M-$2.02B$101.0M$302.0M

R&D Spending

R&D (TTM)
$3.44B
R&D Intensity
57.2%
R&D Growth vs Prior
+67.6%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$1.11B$1.54B$1.88B$2.16B$2.67B$2.99B$3.39B$3.70B$4.24B$5.14B$6.01B
R&D Expense
$581.9M$1.33B$1.20B$1.15B$2.22B$1.46B$1.59B$1.63B$2.61B$2.05B$3.44B
R&D % of Revenue
52.6%86.3%63.7%53.5%83.1%48.8%46.7%44.0%61.5%39.9%57.2%
SG&A
$303.3M$366.3M$434.4M$468.7M$516.9M$739.6M$1.00B$1.16B$1.22B$1.38B$1.43B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$1.11B$1.54B$1.88B$2.16B$2.67B$2.99B$3.39B$3.70B$4.24B$5.14B$6.01B
Cost of Revenue
$58.2M$79.5M$94.1M$114.2M$131.3M$151.0M$207.0M$255.0M$312.1M$372.1M$439.3M
Gross Profit
$1.05B$1.46B$1.79B$2.04B$2.54B$2.84B$3.19B$3.44B$3.93B$4.77B$5.57B
R&D
$581.9M$1.33B$1.20B$1.15B$2.22B$1.46B$1.59B$1.63B$2.61B$2.05B$3.44B
SG&A
$303.3M$366.3M$434.4M$468.7M$516.9M$739.6M$1.00B$1.16B$1.22B$1.38B$1.43B
Operating Income
$145.0M-$243.4M$129.2M$402.0M-$263.7M$585.8M$591.6M$655.4M$101.3M$1.34B$697.7M
Interest Expense
$38.7M$6.9M$1.5M$1.9M$2.2M$1.9M$2.7M$2.6M$2.3M$2.4M$2.3M
Pretax Income
$107.4M-$312.3M$115.3M$486.8M-$232.2M$570.4M$529.1M$834.2M$316.6M$1.66B$796.2M
Net Income
$104.2M-$313.1M$109.5M$446.9M-$295.7M$948.6M$340.7M$597.6M$32.6M$1.29B$403.4M
EPS (Diluted)
0.54-1.530.512.05-1.364.271.522.650.156.411.88
EBITDA
$204.6M-$253.2M$171.9M$543.2M-$178.2M$630.2M$599.6M$919.4M$408.2M$1.76B$872.8M
Shares Out. (M)
194.13204.58215.63217.66218.07222.07223.96225.93210.53200.70203.25

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$652.3M$899.5M$1.16B$1.83B$1.51B$2.06B$2.95B$3.21B$1.69B$3.10B$3.28B
Short-Term Investments
$156.2M$270.1M$274.3M$284.9M$288.4M$290.8M$287.5M$442.7M$470.3M$482.8M$578.7M
Total Current Assets
$994.2M$1.50B$1.83B$2.48B$2.36B$3.12B$4.09B$4.65B$3.24B$5.02B$5.52B
Total Assets
$1.64B$2.30B$2.65B$3.43B$3.56B$4.93B$5.84B$6.78B$5.44B$6.96B$7.29B
Total Current Liabilities
$273.5M$375.4M$425.3M$513.3M$631.2M$854.3M$1.16B$1.24B$1.64B$1.52B$1.44B
Long-Term Debt
$651.5M$16.6M$17.4M$0.00$0.00$0.00$0.00$0.00$0.00$14.5M$0.00
Total Liabilities
$1.22B$672.0M$719.8M$828.3M$949.6M$1.16B$1.47B$1.59B$2.00B$1.80B$1.64B
Stockholders' Equity
$419.5M$1.63B$1.93B$2.60B$2.61B$3.77B$4.37B$5.19B$3.45B$5.17B$5.64B
Retained Earnings
-$1.67B-$1.99B-$1.88B-$1.43B-$1.73B-$777.9M-$437.2M$160.4M-$1.07B$213.8M$317.9M

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$304.8M-$93.0M$336.2M$710.7M-$124.6M$749.5M$969.9M$496.5M$335.3M$1.41B$745.0M
Capital Expenditure
-$120.3M-$111.0M-$73.5M-$78.1M-$187.4M-$181.0M-$77.8M-$32.5M-$86.3M-$58.9M-$60.1M
Free Cash Flow
$184.5M-$204.0M$262.7M$632.6M-$312.0M$568.5M$892.1M$464.0M$249.1M$1.35B$684.9M
Investing Cash Flow
-$232.5M-$350.0M-$86.4M-$87.5M-$269.0M-$207.7M-$78.5M-$207.7M$157.5M-$102.6M-$221.8M
Financing Cash Flow
$58.6M$690.2M$14.7M$45.7M$71.7M$6.2M-$794.0K-$20.0M-$2.02B$101.0M$302.0M
Issuance of Stock
$50.0M$716.2M$29.9M$63.3M$110.3M$58.6M$61.1M$35.8M$49.3M$221.8M$455.6M
Repurchase of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00-$2.00B-$19.1M$0.00
Net Debt Issuance
-$445.0K$0.00$0.00-$822.0K-$836.0K-$2.4M-$2.9M-$3.4M-$3.8M-$4.5M-$4.6M
Stock Based Comp.
$96.2M$133.1M$148.2M$166.6M$177.9M$183.0M$188.4M$215.9M$266.1M$249.3M$263.3M
Net Change in Cash
$130.4M$247.2M$264.5M$668.7M-$319.7M$544.4M$894.0M$262.0M-$1.53B$1.41B$822.6M

Dilution Tracker

Shares Outstanding
204M
5-Year Share Growth
-8.0%
Stock Issuance (TTM)
$455.6M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
194.13204.58215.63217.66218.07222.07223.96225.93210.53200.70203.25
Change vs Prior %
—5.4%5.4%0.9%0.2%1.8%0.8%0.9%-6.8%-4.7%1.3%
Stock Issuance
$50.0M$716.2M$29.9M$63.3M$110.3M$58.6M$61.1M$35.8M$49.3M$221.8M$455.6M
Stock Repurchase
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00-$2.00B-$19.1M$0.00
Stock Based Comp.
$96.2M$133.1M$148.2M$166.6M$177.9M$183.0M$188.4M$215.9M$266.1M$249.3M$263.3M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
94.7%94.8%95.0%94.7%95.1%94.9%93.9%93.1%92.6%92.8%92.7%
Operating Margin %
13.1%-15.8%6.9%18.6%-9.9%19.6%17.4%17.7%2.4%26.1%11.6%
Net Margin %
9.4%-20.4%5.8%20.7%-11.1%31.8%10.0%16.2%0.8%25.0%6.7%
EBITDA Margin %
18.5%-16.5%9.1%25.2%-6.7%21.1%17.7%24.9%9.6%34.2%14.5%
FCF Margin %
16.7%-13.3%14.0%29.3%-11.7%19.0%26.3%12.6%5.9%26.3%11.4%
ROE %
24.8%-19.2%5.7%17.2%-11.3%25.2%7.8%11.5%0.9%24.9%7.1%
ROA %
6.4%-13.6%4.1%13.0%-8.3%19.2%5.8%8.8%0.6%18.5%5.5%
ROIC %
10.3%-12.6%5.5%12.5%-9.0%14.3%8.1%8.5%0.3%20.6%6.0%
R&D / Revenue %
52.6%86.3%63.7%53.5%83.1%48.8%46.7%44.0%61.5%39.9%57.2%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
46.7%38.9%22.5%14.7%23.5%12.0%13.7%8.9%14.8%21.2%
Gross Profit
44.1%39.1%22.7%14.4%24.0%11.8%12.4%7.9%14.2%21.4%
Operating Income
186.3%-267.9%153.1%211.1%-165.6%322.2%1.0%10.8%-84.5%1225.6%
Net Income
1495.8%-400.5%135.0%308.2%-166.2%420.8%-64.1%75.4%-94.5%3845.0%
EPS (Diluted)
1700.0%-383.3%133.3%302.0%-166.3%414.0%-64.4%74.3%-94.3%4173.3%
Operating Cash Flow
252.2%-130.5%461.6%111.4%-117.5%701.5%29.4%-48.8%-32.5%321.5%
Free Cash Flow
204.8%-210.6%228.8%140.8%-149.3%282.2%56.9%-48.0%-46.3%443.9%
R&D Expense
21.3%127.9%-9.7%-3.7%92.0%-34.2%8.8%2.6%60.2%-21.4%
SG&A Expense
54.2%20.8%18.6%7.9%10.3%43.1%35.5%15.3%5.7%12.6%
Total Assets
62.6%40.5%14.9%29.5%3.9%38.5%18.4%16.1%-19.7%27.8%
Book Value / Share
134.3%257.0%13.8%33.3%-1.0%42.8%15.1%17.9%-28.3%58.6%
Debt
5.1%-96.3%50.5%66.7%-21.1%-5.7%-7.5%-7.6%13.7%59.4%
Diluted Shares
3.6%5.4%5.4%0.9%0.2%1.8%0.8%0.9%-6.8%-4.7%

Valuation

P/E (TTM)56.98
10Y Low / Med / High14.99 / 52.50 / 431.69
P/S4.06
10Y Low / Med / High3.37 / 7.11 / 17.04
P/B4.31
10Y Low / Med / High2.71 / 7.01 / 44.91
EV/EBITDA24.23
10Y Low / Med / High9.23 / 31.02 / 92.08
EV/Revenue3.52
10Y Low / Med / High2.94 / 6.56 / 17.04
P/FCF35.61
10Y Low / Med / High14.23 / 30.26 / 102.11

Intrinsic Value Models (per share)

DCF Value
$113.08
Tangible Book / Share
$26.60
Net Current Assets / Share
$19.02
Graham Number
$35.21
Graham Net-Net
$15.77
Cash / Share
$18.97
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
182.31-61.90122.2941.98-63.9617.0752.5023.52431.6914.9956.98
P/S Ratio
17.0412.617.188.697.115.425.253.803.373.754.06
P/B Ratio
44.9111.887.017.227.264.294.082.714.153.734.31
EV/EBITDA
92.08-73.0672.0231.29-98.2022.4824.8811.8231.029.2324.23
EV/Revenue
17.0412.046.587.876.564.744.402.942.993.163.52

Analyst Estimates & Quality

Altman Z-Score
10.82
Safe
Piotroski F-Score
6
Moderate

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$6.04B$6.28B$6.61B
Net Income$694.3M$1.64B$1.94B
EPS$3.21$8.16$9.17
# Analysts (EPS)141612

Revenue Segments

By Product

Segment201920202021202220242025
I C L U S I G$90.0M$105.0M$4.7M$105.8M$114.3M$134.1M
J A K A F I$1.91B$2.22B$338.0M$2.74B$3.21B$3.55B
Milestone And Contract Revenue$77.5M$205.0M$95.0M$165.0M$43.0M$150.0M
Olumiant Royalty$80.4M$110.9M$220.9M$134.5M$135.6M$144.6M
PEMAZYRE Royalty Revenues—$25.9M$109.4M$84.7M$83.9M$86.7M
Tabrecta Royalty Revenues—$4.1M$10.4M$15.4M$22.7M$26.7M
M I N J U V I——$68.5M$19.7M$119.2M$144.6M
OPZELURA——$4.9M$128.7M$508.3M$678.5M
ZYNYZ————$3.2M$66.4M

By Geography

Segment201920202021202220242025
Europe$90.0M$105.0M$124.1M$147.0M$260.4M$323.7M
U [S]—$2.60B$2.90B—$4.00B$4.80B
UNITED STATES———$3.20B——